Current studentsExisting staffContact us
 

N-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease

Simple item page
dc.contributor.authorBarden, A.
dc.contributor.authorBurke, V.
dc.contributor.authorMas, E.
dc.contributor.authorBeilin, L.
dc.contributor.authorPuddey, I.
dc.contributor.authorWatts, G.
dc.contributor.authorIrish, A.
dc.contributor.authorMori, T.
dc.date.issued2015
dc.description.abstractBackground: Metabolism of arachidonic acid by cytochrome P450 [omega]-hydroxylase leads to the formation of 20-hydroxyeicosatetraenoic acid (20-HETE) that regulates vascular function, sodium homeostasis and blood pressure (BP). Supplementation with n-3 fatty acids is known to alter arachidonic acid metabolism and reduce the formation of the lipid peroxidation products F2-isoprostanes, but the effect of n-3 fatty acids on 20-HETE has not been studied. Method: We previously reported a significant effect of n-3 fatty acids but not coenzyme Q10 (CoQ) to reduce BP in a double-blind, placebo-controlled intervention, wherein patients with chronic kidney disease (CKD) were randomized to n-3 fatty acids (4 g), CoQ (200 mg), both supplements or control (4 g olive oil), daily for 8 weeks. This study examined the effect of n-3 fatty acids on plasma and urinary 20-HETE in the same study, as well as plasma and urinary F2-isoprostanes, and relate these to changes in BP. Results: Seventy-four patients completed the 8-week intervention. n-3 fatty acids but not CoQ significantly reduced plasma 20-HETE (P = 0.001) and F2-isoprostanes (P < 0.001). In regression models adjusted for BP at baseline, postintervention plasma 20-HETE was a significant predictor of the fall in SBP (P < 0.0001) and DBP (P < 0.0001) after n-3 fatty acids. Conclusion: This is the first report that n-3 fatty acid supplementation reduces plasma 20-HETE in humans and that this associates with reduced BP. These results provide a plausible mechanism for the reduction in BP observed in patients with CKD following n-3 fatty acid supplementation.
dc.description.statementofresponsibilityAnne E. Barden, Valerie Burke, Emilie Mas, Lawrence J. Beilin, Ian B. Puddey, Gerald F. Watts, Ashley B. Irish and Trevor A. Mori
dc.identifier.citationJournal of Hypertension, 2015; 33(9):1947-1953
dc.identifier.doi10.1097/HJH.0000000000000621
dc.identifier.issn0263-6352
dc.identifier.issn1473-5598
dc.identifier.orcidMas, E. [0000-0003-2848-9613]
dc.identifier.urihttp://hdl.handle.net/2440/104968
dc.language.isoen
dc.publisherLippincott Williams & Wilkins
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/303151
dc.relation.granthttp://purl.org/au-research/grants/nhmrc/1010495
dc.rightsCopyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.
dc.source.urihttps://doi.org/10.1097/hjh.0000000000000621
dc.subject20-hydroxyeicosatetraenoic acid; chronic kidney disease; F2-isoprostanes; n-3 fatty acid supplementation
dc.titleN-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease
dc.typeJournal article
pubs.publication-statusPublished

Files

Collections

Medicine publications